Table 5. Studies with panitumumab and gefitinib chemoradiation.
| No of pts* | Fluoropyrimidine | Biol Agent | RT dose | G3/G4 diarrhoea | PCR** | Good TRG*** | |
|---|---|---|---|---|---|---|---|
| Czito 2006 (59) | 6 | Capecitabine 650 mg/m2 bid | Gefitinib | 50.4 Gy/28#/38 | 16% | 0/6 | No data |
| Valentini 2008 (60) | 33 | 5-FU 225 mg/m2 PVI + | Gefitinib | 50.4 Gy/28#/38 +10 Gy IORT | 12.8% | 10/33 [30%] | 7/33 [21%] |
| Star-02 Pinto 2011 (61) | 60 | 5-FU 225 mg/m2 PVI + Oxaliplatin | Panitumumab | 50.4 Gy/28#/38 | 39% | 12/60 [20%] | No data |
| Blaszkowsky 2009 (62) | 15 | 5-FU 225 mg/m2 PVI + | Bevacizumab and erlotinib | 50.4 Gy/28#/38 | 24% | 7/15 [47%] | No data |
| Helbling 2013 (63) | 40 | Capectabine | Panitumumab | 50.4 Gy/28#/38 | 10% | 4/40 [10%] | 17/40 [43%] |
| Total | 154 | 27/99 | 33/154 [21%] | 24/73 [33%] |
RT, radiotherapy; PCR, pathological complete response; R0 resection, curative resection; TRG, tumour regression grade; (.), reference number; FUFA, 5-FU and folinic acid; RT, radiotherapy; PCR, pathological complete response; OS, overall survival